NCT00878449 - A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Solid Tumors

Interventions

DRUG

ABT-263

150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

DRUG

etoposide/cisplatin

etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles

Trial Locations (7)

21231

Site Reference ID/Investigator# 12303, Baltimore

48202

Site Reference ID/Investigator# 43505, Detroit

60153

Site Reference ID/Investigator# 12841, Maywood

60637

Site Reference ID/Investigator# 13323, Chicago

02215

Site Reference ID/Investigator# 12305, Boston

Site Reference ID/Investigator# 20381, Boston

08901

Site Reference ID/Investigator# 13322, New Brunswick